AstraZeneca plans to invest $50 billion in US by 2030
This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production.
The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas.
WAM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
01-08-2025
- Zawya
Pharma drags London stocks lower after Trump's tariff blitz
British equities slipped on Friday, pressured by healthcare shares, as investors woke up to U.S. President Donald Trump's fresh levies on dozens of countries and demands to lower prescription drug prices. The blue-chip FTSE 100 was down 0.7% as of 0915 GMT, on track to snap a six-week winning streak. The domestically focused midcap FTSE 250 fell nearly 1% and headed for its second straight weekly decline. Late on Thursday, Trump slapped steep tariffs on exports from dozens of trading partners including Canada, Brazil, India, Taiwan and Switzerland, pressing ahead with his plans to reorder the global economy. British healthcare stocks dropped the most, down 2.3%, after Trump sent letters to the leaders of 17 major pharmaceutical companies on Thursday, including AstraZeneca and GSK, outlining how they should slash U.S. prescription drug prices. AstraZeneca shed 3.4%, while GSK slipped 1.3%. Industrial Support Services sector fell 2.1% after Intertek Group missed its half-year organic revenue growth. The British product testing firm fell the most in the FTSE 100, down 7.7%. British Airways owner IAG dropped 2.1% after the airline group said it expected a slight rise in costs linked to air traffic control issues. Watches of Switzerland was the biggest drag on the FTSE 250, down 8%, after the U.S. imposed a 39% tariff on Swiss imports. Conversely, Melrose Industries rose 6.5% to the top of the benchmark index, after the defence company beat operating profit expectations on strong demand. Pearson rose 4.5% after the British education company forecast stronger growth in the second half. Meanwhile, Britain said the European Union will remove tariffs on key steel products under a quota system from Friday as part of a reset of ties and a recent deal to ease trade barriers. However, London is yet to conclude negotiations with the U.S. after both sides agreed in May to work toward removing tariffs on British steel exports. Also, data showed on Friday that British house prices rose slightly faster than expected in July. (Reporting by Sanchayaita Roy in Bengaluru; Editing by Sahal Muhammed)
Zawya
01-08-2025
- Zawya
AstraZeneca enters rare disease care in South Africa
AstraZeneca announced its entrance into rare disease care in South Africa at a launch event held at the Nelson Mandela Children's Hospital in Johannesburg. Its rare disease portfolio will bring treatments for complex conditions such as neurofibromatosis type 1 (NF1), paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), and myasthenia gravis. The event included a panel discussion with experts from fields such as neuro-oncology, neurology, plastic surgery, and genetics. Panellists highlighted the vital need for coordinated, specialist-driven care and robust collaboration across public and private sectors to ensure that patients receive integrated support at every stage of their journey. Dr Nkuli Boikhutso, CEO of Nelson Mandela Children's Hospital, stated: 'We are honoured to be the site of this important milestone. "AstraZeneca's commitment to introducing new treatments for rare diseases offers hope for our young patients and aligns with our vision to provide world-class, specialised care for all children, regardless of their background.' Rare diseases Around the world, more than 400 million people are affected by over 10,000 known rare diseases, yet the vast majority of these conditions have no approved treatments. For many rare disease patients and their families, this often results in years of uncertainty, misdiagnosis, and limited or difficult treatment options. AstraZeneca is dedicated to transforming this landscape by introducing advanced therapies, supporting earlier and more accurate diagnoses, and fostering multidisciplinary collaboration. 'AstraZeneca's entry into the rare disease space in South Africa is both a proud and hopeful moment for us,' said Deepak Arora, African cluster country president at AstraZeneca. 'Building on decades of pioneering rare disease science, we are committed to expanding access to transformational medicines for conditions such as NF1, PNH. 'This marks a significant milestone in our mission to improve the lives of patients living with rare diseases, especially children who have had very few options until now.' AstraZeneca's rare disease strategy in Africa is anchored in three key priorities: accelerating access to vital medicines, driving innovation through research and development, and expanding its global reach to make meaningful change. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
Gulf Today
23-07-2025
- Gulf Today
AstraZeneca plans to invest $50 billion in US by 2030
AstraZeneca has announced a $50 billion investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas. WAM
